Using the established cutoff for myocardial infarction (≥10 pmol/L), copeptin had a sensitivity of 80.8% (CI 72.2–87.2), a specificity of 63.6% (CI 56.9–69.9), a PPV of 52.5% (CI 44.8–60.1), a NPV of 86.9% (CI 80.7–91.4), a LR+ of 2.22 (CI 1.81–2.72) and a LR− of 0.3 (CI 0.2–0.45) for AAS. This evidence concerns the gene AVP and myocardial infarction.